No-shpa, 40 mg tablets 64 pcs

Interaction

With levodopa

Papaverine-like phosphodiesterase inhibitors reduce the antiparkinsonian effect of levodopa. When drotaverine is administered simultaneously with levodopa, stiffness and tremor may increase. With other antispasmodic agents, including m-cholinoblockers

Special Instructions

No-Spa® 40 mg tablets contain 52 mg of lactose. This may cause gastrointestinal complaints in persons with lactose intolerance. This form is unacceptable for patients with lactose deficiency, galactosemia or impaired glucose/galactose absorption syndrome (see section “Contraindications”).

Contraindications

• High sensitivity to the active ingredient or any of the excipients of the drug
• Severe hepatic or renal impairment
• Severe heart failure (low cardiac output syndrome)
• Childhood under 6 years
• Breast-feeding period (no clinical data).
• Rare hereditary galactose intolerance, lactase deficiency and glucose-galactose malabsorption syndrome (due to the presence of lactose in the drug).

With caution:
– In arterial hypotension.
– In children (insufficient clinical experience of use).
– In pregnant women (see section “Pregnancy and lactation”).
.

Side effects

Adverse reactions observed in clinical trials are presented below, divided by system, organ, and frequency according to the following gradations: Very frequent (≥10%), frequent (≥1%, < 10); infrequent (≥0.1%, < 1%); rare (≥0.01%, < 0.1%) and very rare, including individual reports (< 0.01%), unknown frequency (frequency cannot be determined from available data).

Overdose

There are no data on overdose of the drug.

Similarities

No-shpa, Drotaverine, Spasmonet, Drotaverine-Teva